X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AVB-101 is an investigational gene therapy that contains a correct (non-mutated) version of the GRN gene. It is being evaluated for the treatment of frontotemporal dementia with GRN mutations.
Lead Product(s): AVB-101
Therapeutic Area: Neurology Product Name: AVB-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
AVB-101 is an investigational gene therapy delivered as a one-time infusion directly to the brain, enabling distribution to brain areas affected by FTD while limiting systemic exposure.
Lead Product(s): AVB-101
Therapeutic Area: Neurology Product Name: AVB-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
AVB-101 is an investigational gene therapy designed to halt disease progression by delivering a functional copy of the GRN gene to restore appropriate progranulin levels in the brain for the treatment of frontotemporal dementia.
Lead Product(s): AVB-101
Therapeutic Area: Neurology Product Name: AVB-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
In pre-clinical pharmacology studies, AVB-101 administration via intrathalamic injection, in a progranulin-deficient mouse model, demonstrated neuronal specific PGRN brain expression and reduction in disease pathology.
Lead Product(s): AVB-101
Therapeutic Area: Neurology Product Name: AVB-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
AVB-101 is an investigational AAV gene therapy designed to slow or stop disease progression by delivering a functional copy of the GRN gene throughout the central nervous system to restore progranulin levels.
Lead Product(s): AVB-101
Therapeutic Area: Neurology Product Name: AVB-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
AVB-101, an investigational, adeno-associated virus gene therapy designed for patients with FTD with mutations in progranulin gene, designed to slow or arrest disease progression by delivering a functional copy of GRN gene throughout CNS to restore normal progranulin levels.
Lead Product(s): AVB-101
Therapeutic Area: Neurology Product Name: AVB-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
The funds will be used to advance AviadoBio’s lead program AVB-PGRN, in frontotemporal dementia (FTD) into the clinic, progress its preclinical assets, including for amyotrophic lateral sclerosis (ALS), whilst continuing to expand its industry-leading team.
Lead Product(s): AVB-PGRN
Therapeutic Area: Neurology Product Name: AVB-PGRN
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: New Enterprise Associates
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
